DE69102627D1 - Verbesserte cyclodextrin enthaltende erythropoietin-formulierung. - Google Patents

Verbesserte cyclodextrin enthaltende erythropoietin-formulierung.

Info

Publication number
DE69102627D1
DE69102627D1 DE69102627T DE69102627T DE69102627D1 DE 69102627 D1 DE69102627 D1 DE 69102627D1 DE 69102627 T DE69102627 T DE 69102627T DE 69102627 T DE69102627 T DE 69102627T DE 69102627 D1 DE69102627 D1 DE 69102627D1
Authority
DE
Germany
Prior art keywords
formulation containing
erythropoietin
containing cyclodextrin
gamma
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69102627T
Other languages
English (en)
Other versions
DE69102627T2 (de
Inventor
Frank Konings
Marcus Noppe
Jean Mesens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69102627(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69102627D1 publication Critical patent/DE69102627D1/de
Publication of DE69102627T2 publication Critical patent/DE69102627T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
DE69102627T 1990-01-29 1991-01-25 Verbesserte cyclodextrin enthaltende erythropoietin-formulierung. Revoked DE69102627T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation
PCT/EP1991/000173 WO1991011200A1 (en) 1990-01-29 1991-01-25 Improved cyclodextrin based erythropoietin formulation

Publications (2)

Publication Number Publication Date
DE69102627D1 true DE69102627D1 (de) 1994-07-28
DE69102627T2 DE69102627T2 (de) 1994-11-03

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69102627T Revoked DE69102627T2 (de) 1990-01-29 1991-01-25 Verbesserte cyclodextrin enthaltende erythropoietin-formulierung.

Country Status (20)

Country Link
US (1) US5376632A (de)
EP (1) EP0513072B1 (de)
JP (1) JP2997052B2 (de)
KR (1) KR0183445B1 (de)
AT (1) ATE107518T1 (de)
AU (1) AU648061B2 (de)
CA (1) CA2074820C (de)
DE (1) DE69102627T2 (de)
DK (1) DK0513072T3 (de)
ES (1) ES2059115T3 (de)
FI (1) FI105012B (de)
GB (1) GB9001987D0 (de)
HU (1) HU218213B (de)
IE (1) IE65209B1 (de)
IL (1) IL97019A (de)
NO (1) NO304728B1 (de)
NZ (1) NZ236938A (de)
PT (1) PT96593B (de)
WO (1) WO1991011200A1 (de)
ZA (1) ZA91620B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
EP0954326B2 (de) 1996-04-19 2009-07-22 Grifols Inc. Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
WO1998041226A1 (de) * 1997-03-18 1998-09-24 Roche Diagnostics Gmbh Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
BR0010665A (pt) * 1999-04-09 2004-03-09 Ortho Mcneil Pharm Inc ComposiçÈes farmacêuticas de eritropoietina
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
JPWO2003006052A1 (ja) * 2001-07-09 2005-02-17 山之内製薬株式会社 徐放性注射剤用組成物およびその製造方法
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
CN101528215B (zh) 2006-10-20 2011-10-19 艾科斯有限公司 Chk1抑制剂和环糊精的组合物
DK2590666T3 (en) * 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
HU9202432D0 (en) 1992-10-28
NO304728B1 (no) 1999-02-08
EP0513072B1 (de) 1994-06-22
DE69102627T2 (de) 1994-11-03
FI923402A (fi) 1992-07-28
JP2997052B2 (ja) 2000-01-11
KR0183445B1 (en) 1999-05-01
CA2074820C (en) 2003-10-14
NO922990D0 (no) 1992-07-29
ZA91620B (en) 1992-10-28
NZ236938A (en) 1992-07-28
AU7149791A (en) 1991-08-21
DK0513072T3 (da) 1994-08-01
IL97019A (en) 1997-07-13
NO922990L (no) 1992-07-29
IE65209B1 (en) 1995-10-04
AU648061B2 (en) 1994-04-14
EP0513072A1 (de) 1992-11-19
HUT62198A (en) 1993-04-28
PT96593A (pt) 1991-10-15
ATE107518T1 (de) 1994-07-15
JPH05503700A (ja) 1993-06-17
HU218213B (hu) 2000-06-28
FI105012B (fi) 2000-05-31
ES2059115T3 (es) 1994-11-01
WO1991011200A1 (en) 1991-08-08
PT96593B (pt) 2001-06-29
IE910286A1 (en) 1991-07-31
IL97019A0 (en) 1992-03-29
GB9001987D0 (en) 1990-03-28
CA2074820A1 (en) 1991-07-30
FI923402A0 (fi) 1992-07-28
US5376632A (en) 1994-12-27

Similar Documents

Publication Publication Date Title
ATE107518T1 (de) Verbesserte cyclodextrin enthaltende erythropoietin-formulierung.
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
NL980012I1 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
HU200943B (en) Process for producing pharmaceutical compositions comprising active ingredients which are instable or badly soluble in water
ATE297433T1 (de) Filmbildende zusammensetzungen aus pullulan
FI891570A (fi) Menetelmä piroksikaamia sisältävän farmaseuttisen koostumuksen valmistamiseksi
IT9019829A0 (it) Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
ATE132518T1 (de) Hilfstoffzusammensetzungen in fester form dispergierbar in wasserigen medien und verfahren zur herstellung davon
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DK0422497T3 (da) Inklusionskomplekser med Silybinin, deres fremstilling af farmaceutiske præparater, der indeholder dem
MD679F1 (en) Inclusion complex of N-ethoxycarbonyl-3-morpholinsydnonimine or salts thereof with cyclodextrin or its derivatives, preparation thereof and pharmaceutical compositions containing them, method of preparation thereof and treatment method
SE9004169D0 (sv) Anvaendning av farmaceutiska och kosmetiska kompositioner, innehaallande 1,8-dihydroxi-10-fenyl-9-antron som verksam bestaandsdel
IT1264495B1 (it) Complessi solubili in acqua di glicosaminoglicani, loro procedimento di preparazione e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation